Truvestments Capital LLC Has $206,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Truvestments Capital LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 9.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 791 shares of the medical research company’s stock after purchasing an additional 69 shares during the period. Truvestments Capital LLC’s holdings in Amgen were worth $206,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Hopwood Financial Services Inc. acquired a new position in shares of Amgen during the fourth quarter valued at about $418,000. Sequoia Financial Advisors LLC raised its holdings in shares of Amgen by 6.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 143,836 shares of the medical research company’s stock valued at $37,489,000 after purchasing an additional 9,254 shares during the period. Summit X LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $455,000. Natural Investments LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $1,248,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $80,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 2.0 %

Amgen stock opened at $312.50 on Thursday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a 50 day moving average price of $289.70 and a 200-day moving average price of $299.52. The company has a market capitalization of $167.88 billion, a P/E ratio of 41.39, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Leerink Partners lowered their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. UBS Group restated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.